Date: February 16, 2024
Attention: All Providers
Effective: February 12, 2024
Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective February 12, 2024, sirolimus tablets and generics will now be preferred. This is in response to the discontinuation of the brand product Rapamune by the manufacturer.
How this impacts providers: The change will allow providers to prescribe the generic without requiring Preferred Drug List (PDL) prior authorization at this time and continue accessing necessary medication for their patients.
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.